Diabetic Macular Oedema Guidelines: An Australian Perspective
The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, di...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2023-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2023/6329819 |
| _version_ | 1826992776251703296 |
|---|---|
| author | Yew Sen Yuen Jagjit Singh Gilhotra Michelle Dalton Jaskirat S. Aujla Hemal Mehta Sanj Wickremasinghe Gurmit Uppal Jennifer Arnold Fred Chen Andrew Chang Samantha Fraser-Bell Lyndell Lim Janika Shah Ellie Bowditch Geoffrey K. Broadhead |
| author_facet | Yew Sen Yuen Jagjit Singh Gilhotra Michelle Dalton Jaskirat S. Aujla Hemal Mehta Sanj Wickremasinghe Gurmit Uppal Jennifer Arnold Fred Chen Andrew Chang Samantha Fraser-Bell Lyndell Lim Janika Shah Ellie Bowditch Geoffrey K. Broadhead |
| author_sort | Yew Sen Yuen |
| collection | DOAJ |
| description | The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy (DR)). In one study examining the global prevalence of DR, 35% of people with diabetes had some form of DR, 7% had PDR, 7% had DMO, and 10% were affected by these vision-threatening stages. In many regions of the world (Australia included), DR is one of the top three leading causes of vision loss amongst working age adults (20–74 years). In the management of DMO, the landmark ETDRS study demonstrated that moderate visual loss, defined as doubling of the visual angle, can be reduced by 50% or more by focal/grid laser photocoagulation. However, over the last 20 years, antivascular endothelial growth factor (VEGF) and corticosteroid therapies have emerged as alternative options for the management of DMO and provided patients with choices that have higher chances of improving vision than laser alone. In Australia, since the 2008 NHMRC guidelines, there have been significant developments in both the treatment options and treatment schedules for DMO. This working group was therefore assembled to review and address the current management options available in Australia. |
| first_indexed | 2024-04-10T05:24:42Z |
| format | Article |
| id | doaj.art-5c93faac2fea4018909356705a05de19 |
| institution | Directory Open Access Journal |
| issn | 2090-0058 |
| language | English |
| last_indexed | 2025-02-18T08:54:46Z |
| publishDate | 2023-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj.art-5c93faac2fea4018909356705a05de192024-11-02T23:56:13ZengHindawi LimitedJournal of Ophthalmology2090-00582023-01-01202310.1155/2023/6329819Diabetic Macular Oedema Guidelines: An Australian PerspectiveYew Sen Yuen0Jagjit Singh Gilhotra1Michelle Dalton2Jaskirat S. Aujla3Hemal Mehta4Sanj Wickremasinghe5Gurmit Uppal6Jennifer Arnold7Fred Chen8Andrew Chang9Samantha Fraser-Bell10Lyndell Lim11Janika Shah12Ellie Bowditch13Geoffrey K. Broadhead14National University HospitalRoyal Adelaide HospitalDalton & Associates Inc.South Australian Institute of OphthalmologySave Sight RegistriesCentre for Eye Research AustraliaMoreton Eye GroupMarsden Eye SpecialistsCentre for Ophthalmology and Visual Sciences (Incorporating Lions Eye Institute)Sydney Institute of Vision ScienceDepartment of OphthalmologyCentre for Eye Research AustraliaSydney Eye HospitalSave Sight InstituteSave Sight InstituteThe number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy (DR)). In one study examining the global prevalence of DR, 35% of people with diabetes had some form of DR, 7% had PDR, 7% had DMO, and 10% were affected by these vision-threatening stages. In many regions of the world (Australia included), DR is one of the top three leading causes of vision loss amongst working age adults (20–74 years). In the management of DMO, the landmark ETDRS study demonstrated that moderate visual loss, defined as doubling of the visual angle, can be reduced by 50% or more by focal/grid laser photocoagulation. However, over the last 20 years, antivascular endothelial growth factor (VEGF) and corticosteroid therapies have emerged as alternative options for the management of DMO and provided patients with choices that have higher chances of improving vision than laser alone. In Australia, since the 2008 NHMRC guidelines, there have been significant developments in both the treatment options and treatment schedules for DMO. This working group was therefore assembled to review and address the current management options available in Australia.http://dx.doi.org/10.1155/2023/6329819 |
| spellingShingle | Yew Sen Yuen Jagjit Singh Gilhotra Michelle Dalton Jaskirat S. Aujla Hemal Mehta Sanj Wickremasinghe Gurmit Uppal Jennifer Arnold Fred Chen Andrew Chang Samantha Fraser-Bell Lyndell Lim Janika Shah Ellie Bowditch Geoffrey K. Broadhead Diabetic Macular Oedema Guidelines: An Australian Perspective Journal of Ophthalmology |
| title | Diabetic Macular Oedema Guidelines: An Australian Perspective |
| title_full | Diabetic Macular Oedema Guidelines: An Australian Perspective |
| title_fullStr | Diabetic Macular Oedema Guidelines: An Australian Perspective |
| title_full_unstemmed | Diabetic Macular Oedema Guidelines: An Australian Perspective |
| title_short | Diabetic Macular Oedema Guidelines: An Australian Perspective |
| title_sort | diabetic macular oedema guidelines an australian perspective |
| url | http://dx.doi.org/10.1155/2023/6329819 |
| work_keys_str_mv | AT yewsenyuen diabeticmacularoedemaguidelinesanaustralianperspective AT jagjitsinghgilhotra diabeticmacularoedemaguidelinesanaustralianperspective AT michelledalton diabeticmacularoedemaguidelinesanaustralianperspective AT jaskiratsaujla diabeticmacularoedemaguidelinesanaustralianperspective AT hemalmehta diabeticmacularoedemaguidelinesanaustralianperspective AT sanjwickremasinghe diabeticmacularoedemaguidelinesanaustralianperspective AT gurmituppal diabeticmacularoedemaguidelinesanaustralianperspective AT jenniferarnold diabeticmacularoedemaguidelinesanaustralianperspective AT fredchen diabeticmacularoedemaguidelinesanaustralianperspective AT andrewchang diabeticmacularoedemaguidelinesanaustralianperspective AT samanthafraserbell diabeticmacularoedemaguidelinesanaustralianperspective AT lyndelllim diabeticmacularoedemaguidelinesanaustralianperspective AT janikashah diabeticmacularoedemaguidelinesanaustralianperspective AT elliebowditch diabeticmacularoedemaguidelinesanaustralianperspective AT geoffreykbroadhead diabeticmacularoedemaguidelinesanaustralianperspective |